KA
Therapeutic Areas
Syndax Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Revumenib (SNDX-5613) | Relapsed/Refractory KMT2A-rearranged (KMT2Ar) Acute Leukemia | Phase 2/3 |
| Axatilimab (SNDX-6352) | Chronic Graft-versus-Host Disease (cGVHD) after 2+ prior lines | Phase 2/3 |
Leadership Team at Syndax Pharmaceuticals
MA
Michael A. Metzger
Chief Executive Officer and Director
NG
Neil Gallagher, M.D., Ph.D.
President, Head of Research and Development
AG
Anjali Ganguli, M.D.
Senior Vice President, Clinical Development
WM
William Meury
Chief Commercial Officer
BB
Brigitte B. Robertson, M.D.
Chief Medical Officer
DG
Dennis G. Hall
Senior Vice President, General Counsel
BD
Bryan D. Ross
Senior Vice President, Corporate Affairs & Investor Relations
DA
Dennis A. Ausiello, M.D.
Director
BW
Briggs W. Morrison, M.D.
Director
MG
Michele G. D. Kessler
Director